Laure Lemarcq, Valerie Reynaert, Ellen Van den Steen, Corinne Evers-Lebrun, Branka Marinović, Diederik De Cock, Jan Gutermuth
{"title":"免疫介导的炎症性皮肤病（skIMIDs）跨学科治疗的结果测量：范围综述。","authors":"Laure Lemarcq, Valerie Reynaert, Ellen Van den Steen, Corinne Evers-Lebrun, Branka Marinović, Diederik De Cock, Jan Gutermuth","doi":"10.1093/bjd/ljaf153","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>There is a growing trend towards interdisciplinary care (IC) for the management of immune-mediated inflammatory skin diseases (skIMIDs). However, an overview of instruments used to evaluate whether IC is superior to usual care is currently lacking.</p><p><strong>Objectives: </strong>This scoping review aims to gain insight into clinician- and patient-reported outcome measures (ClinROMs and PROMs) used in IC for skIMIDs.</p><p><strong>Methods: </strong>A comprehensive literature search was conducted by screening PubMed, Web of Science and Embase databases from their inception until October 2024. To be eligible, studies needed to have investigated IC for skIMIDs involving dermatologists, and have reported either ClinROMs or PROMs. Two independent reviewers screened all records by title, abstract and full text, with conflicts resolved by a third reviewer.</p><p><strong>Results: </strong>Fourteen studies were included in this review. Nine investigated IC for psoriasis (PsO), four for atopic dermatitis (AD) and one for hidradenitis suppurativa. Six PsO studies examined combined dermatology-rheumatology clinics, while four studies explored collaborations with psychiatrists or psychologists for PsO or AD. The remaining IC models were diverse. A total of 49 different ClinROMs and PROMs were reported across the included studies, with 38 being reported by only one study. Except for the Dermatology Life Quality Index (used by 12 studies), body surface area (used by four studies), Psoriasis Area and Severity Index (used by all PsO studies), and Eczema Area and Severity Index or SCORing Atopic Dermatitis (used by all AD studies), the reported ClinROMs and particularly PROMs vary widely.</p><p><strong>Conclusions: </strong>Although several studies describe IC models for skIMIDs, few investigated their impact on ClinROMs or PROMs. The heterogeneous outcomes used pose a challenge for comparison across studies. This review highlights the need for consensus on a core set of outcome measures for IC in skIMIDs to create a common language among the healthcare providers involved, and enhance comparability between studies. Implementing standardized outcome measures for IC in skIMIDs could contribute to the development of evidence-based guidelines and ultimately, improve patient care.</p><p><strong>Graphical abstract: </strong></p>","PeriodicalId":9238,"journal":{"name":"British Journal of Dermatology","volume":" ","pages":"415-423"},"PeriodicalIF":9.6000,"publicationDate":"2025-08-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Outcome measures for interdisciplinary care in immune-mediated inflammatory skin diseases: a scoping review.\",\"authors\":\"Laure Lemarcq, Valerie Reynaert, Ellen Van den Steen, Corinne Evers-Lebrun, Branka Marinović, Diederik De Cock, Jan Gutermuth\",\"doi\":\"10.1093/bjd/ljaf153\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>There is a growing trend towards interdisciplinary care (IC) for the management of immune-mediated inflammatory skin diseases (skIMIDs). However, an overview of instruments used to evaluate whether IC is superior to usual care is currently lacking.</p><p><strong>Objectives: </strong>This scoping review aims to gain insight into clinician- and patient-reported outcome measures (ClinROMs and PROMs) used in IC for skIMIDs.</p><p><strong>Methods: </strong>A comprehensive literature search was conducted by screening PubMed, Web of Science and Embase databases from their inception until October 2024. To be eligible, studies needed to have investigated IC for skIMIDs involving dermatologists, and have reported either ClinROMs or PROMs. Two independent reviewers screened all records by title, abstract and full text, with conflicts resolved by a third reviewer.</p><p><strong>Results: </strong>Fourteen studies were included in this review. Nine investigated IC for psoriasis (PsO), four for atopic dermatitis (AD) and one for hidradenitis suppurativa. Six PsO studies examined combined dermatology-rheumatology clinics, while four studies explored collaborations with psychiatrists or psychologists for PsO or AD. The remaining IC models were diverse. A total of 49 different ClinROMs and PROMs were reported across the included studies, with 38 being reported by only one study. Except for the Dermatology Life Quality Index (used by 12 studies), body surface area (used by four studies), Psoriasis Area and Severity Index (used by all PsO studies), and Eczema Area and Severity Index or SCORing Atopic Dermatitis (used by all AD studies), the reported ClinROMs and particularly PROMs vary widely.</p><p><strong>Conclusions: </strong>Although several studies describe IC models for skIMIDs, few investigated their impact on ClinROMs or PROMs. The heterogeneous outcomes used pose a challenge for comparison across studies. This review highlights the need for consensus on a core set of outcome measures for IC in skIMIDs to create a common language among the healthcare providers involved, and enhance comparability between studies. Implementing standardized outcome measures for IC in skIMIDs could contribute to the development of evidence-based guidelines and ultimately, improve patient care.</p><p><strong>Graphical abstract: </strong></p>\",\"PeriodicalId\":9238,\"journal\":{\"name\":\"British Journal of Dermatology\",\"volume\":\" \",\"pages\":\"415-423\"},\"PeriodicalIF\":9.6000,\"publicationDate\":\"2025-08-18\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"British Journal of Dermatology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1093/bjd/ljaf153\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"DERMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"British Journal of Dermatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/bjd/ljaf153","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"DERMATOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
背景：在免疫介导的炎症性皮肤病（skIMIDs）的治疗中，跨学科治疗（IC）的趋势越来越明显。然而，目前缺乏用于评估IC是否优于常规护理的工具概述。目的：本综述旨在深入了解在IC中用于skIMIDs的临床医生和患者报告的结果测量（clinrom和PROMs）。方法：通过筛选PubMed、Web of Science和Embase数据库，从其建立到2024年10月进行全面的文献检索。符合条件的研究必须调查IC中涉及皮肤科医生的skimid，并报告clinrom或prom。两名独立审稿人按标题、摘要和全文筛选所有记录，冲突由第三名审稿人解决。结果：本综述纳入了14项研究。9例为银屑病（PsO）， 4例为特应性皮炎（AD）， 1例为化脓性汗腺炎。6项PsO研究检查了皮肤科-风湿病学联合诊所，而4项研究探索了与精神病学家或心理学家合作治疗PsO或AD。剩下的IC型号多种多样。在纳入的研究中，总共报告了49种不同的clinrom和prom，其中38种仅由一项研究报告。除了皮肤病生活质量指数（DLQI，由12项研究使用）、体表面积（BSA，由4项研究使用）、牛皮癣面积严重程度指数（PASI，由所有PsO研究使用）和湿疹面积和严重程度指数或评分特应性皮炎指数（EASI或SCORAD指数，由所有AD研究使用）外，报告的clinrom，特别是PROMs差异很大。结论：虽然有一些研究描述了skIMIDs的IC模型，但很少研究它们对clinrom或prom的影响。使用的异质性结果对跨研究比较提出了挑战。这篇综述强调了在skIMIDs中IC的核心结果衡量标准上达成共识的必要性，以便在相关的卫生保健提供者之间建立一种共同的语言，并增强研究之间的可比性。在skIMIDs中实施标准化的IC结果测量可以促进循证指南的发展，并最终改善患者护理。
Outcome measures for interdisciplinary care in immune-mediated inflammatory skin diseases: a scoping review.
Background: There is a growing trend towards interdisciplinary care (IC) for the management of immune-mediated inflammatory skin diseases (skIMIDs). However, an overview of instruments used to evaluate whether IC is superior to usual care is currently lacking.
Objectives: This scoping review aims to gain insight into clinician- and patient-reported outcome measures (ClinROMs and PROMs) used in IC for skIMIDs.
Methods: A comprehensive literature search was conducted by screening PubMed, Web of Science and Embase databases from their inception until October 2024. To be eligible, studies needed to have investigated IC for skIMIDs involving dermatologists, and have reported either ClinROMs or PROMs. Two independent reviewers screened all records by title, abstract and full text, with conflicts resolved by a third reviewer.
Results: Fourteen studies were included in this review. Nine investigated IC for psoriasis (PsO), four for atopic dermatitis (AD) and one for hidradenitis suppurativa. Six PsO studies examined combined dermatology-rheumatology clinics, while four studies explored collaborations with psychiatrists or psychologists for PsO or AD. The remaining IC models were diverse. A total of 49 different ClinROMs and PROMs were reported across the included studies, with 38 being reported by only one study. Except for the Dermatology Life Quality Index (used by 12 studies), body surface area (used by four studies), Psoriasis Area and Severity Index (used by all PsO studies), and Eczema Area and Severity Index or SCORing Atopic Dermatitis (used by all AD studies), the reported ClinROMs and particularly PROMs vary widely.
Conclusions: Although several studies describe IC models for skIMIDs, few investigated their impact on ClinROMs or PROMs. The heterogeneous outcomes used pose a challenge for comparison across studies. This review highlights the need for consensus on a core set of outcome measures for IC in skIMIDs to create a common language among the healthcare providers involved, and enhance comparability between studies. Implementing standardized outcome measures for IC in skIMIDs could contribute to the development of evidence-based guidelines and ultimately, improve patient care.
期刊介绍：
The British Journal of Dermatology (BJD) is committed to publishing the highest quality dermatological research. Through its publications, the journal seeks to advance the understanding, management, and treatment of skin diseases, ultimately aiming to improve patient outcomes.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
